Source comparison
Selank Peptide Same as Selank Amidate: Comparison Table
The following table clarifies the naming conventions, structural features, and practical implications of Selank's chemical identity across research and commercial contexts. Selank Thr-Lys-Pro-Arg-Pro-Gly-Pro-NH₂ (heptapeptide with C-terminal amide) Intranasal,
This comparison does not assign a generated winner or score.
- The following table clarifies the naming conventions, structural features, and practical implications of Selank's chemical identity across research and commercial contexts.
- Selank
- Thr-Lys-Pro-Arg-Pro-Gly-Pro-NH₂ (heptapeptide with C-terminal amide)
- Intranasal, subcutaneous
- 300–900 mcg/day (intranasal), 250–500 mcg/day (subcutaneous)
- Half-life 20–30 minutes; resistant to carboxypeptidase degradation
- Standard nomenclature in research literature; assumes amidate form
- Selank Amidate
- Thr-Lys-Pro-Arg-Pro-Gly-Pro-NH₂ (identical sequence and terminal modification)
- Chemically explicit term emphasizing the amide modification; functionally identical to 'Selank'
- Tuftsin (non-amidated parent)
- Thr-Lys-Pro-Arg (tetrapeptide without terminal modification)
- Requires IV administration; oral bioavailability near zero
- Not used for anxiolytic purposes
- Plasma half-life <60 seconds; rapidly degraded by carboxypeptidases
- No CNS-penetrating anxiolytic effects; immunomodulatory only